ArticleFrontiers in oncology2026
Thermal ablation for visible cervical HSIL or suspected HSIL: a tissue-conserving alternative to excision in selected patients.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study evaluates the feasibility and clinical outcomes of squamocolumnar junction (SCJ)-targeted thermal ablation in patients with visible cervical lesions diagnosed as high-grade squamous intraepithelial lesions (HSIL) or suspected HSIL, and explores changes in CK7-positive SCJ cells following treatment. Methods: In this prospective cohort study, 226 patients meeting predefined eligibility criteria between June 2017 and December 2024 were managed with either SCJ-targeted thermal ablation (n = 110) or loop electrosurgical excision procedure (LEEP, n = 116), based on clinical assessment and patient preference. Outcomes included operative parameters, complications, cytological abnormalities, high-risk HPV (hrHPV) clearance, lesion persistence or recurrence, and changes in CK7-positive SCJ cells in a subset of patients. Results: Baseline clinicopathologic characteristics were broadly comparable between groups, although treatment allocation was non-randomized. SCJ ablation was associated with shorter operative time, minimal intraoperative blood loss, fewer procedure-related complications, and lower treatment cost compared with LEEP ( Conclusion: In carefully selected patients with fully visible transformation zones, SCJ-targeted thermal ablation demonstrated favorable procedural outcomes and similar observed short- to mid-term clinical results compared with LEEP in this observational cohort. These findings support its potential as a tissue-conserving treatment option in selected cases. The reduction in CK7-positive SCJ cells suggests a possible biologic basis for SCJ-targeted therapy, although this remains exploratory. Given the non-randomized design and limited event rates, these findings should be interpreted with caution, and further prospective studies are warranted.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.